The U.S health care system maintains one of the most sophisticated health care delivery systems in the world. However, in spite of the many advances in treatment and technology, a major barrier exists: Nearly half of all U.S. adults lack the skills necessary to read, understand, and act on their own health such as how to take their medications or understand basic health care instructions. This issue is known as low health literacy. Low health literacy is a stronger predictor of health status than age, income, employment, education, race, or ethnicity. An estimated 80 million Americans have low health literacy, which not only causes medical errors, high rates of hospitalization, death, and poor health care outcomes, but is estimated to cost the U.S. economy up to $236 billion annually.
About Health Literacy Innovations:
Health Literacy Innovations (HLI) creates tools to reduce medical mistakes, unnecessary health care costs, and poor health outcomes from low health literacy. HLI’s flagship product, the Health Literacy Advisor™ (HLA) (in Spanish–Asesor de Comunicación en Salud™), is a state-of-the-art interactive health literacy software tool available in multiple platforms, including a web-based model. As a “health literacy checker,” the HLA revolutionizes the labor-intensive health literacy review process by leveraging powerful software to help communicators evaluate, standardize, and produce clear health information. The uniquely-built HLA blends best in-class features for plain language and health literacy compliance that include English and Spanish readability indices, an interactive plain language search-and-replace function, usability, and document assessment tools that rewards users for good work, and more. For more information, please contact [email protected] or call 301-230-4966.
Join this webinar to learn about some key challenges that companies will face in subcontracting biologics production to contract development and manufacturing organizations and how best to address these challenges.
Join experts from Alira Health, Sean Forestell, PhD, Director, CMC Operations; and Steven Chamow, PhD, Senior Vice President, CMC Development, for the live webinar on Wednesday, November 8, 2023, at 1pm PST (4pm EST).
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
EQUIPMENT MANAGEMENT FOR OPTIMAL UPTIME Blue Diamond Herbs is investing in new equipment to elevate its manufacturing capabilities. InstantGMP’s integrated Equipment Log will play a pivotal role in ensuring that this equipment remains in peak working condition, minimizing downtime and enhancing productivity.
EFFICIENT, ACCURATE, AND QUALITY WHITE AND PRIVATE LABEL MANUFACTURING SOLUTIONS Blue Diamond Herbs specializes in white and private-label manufacturing. InstantGMP™ PRO software streamlines these processes by offering external user capabilities, including an Electronic Batch Record (EBR) module with a signoff feature that supports great traceability and a Vendor Management module that allows internal users and external vendors the ability to collaborate, edit, and approve quality documents and business agreements which are automatically uploaded to the integrated Electronic Data Management System (EDMS). Additionally, the EDMS allows Blue Diamond Herbs to establish individual customer product specifications.
MAKE-TO-ORDER ELECTRONIC BATCH RECORD MODULE FOR SAMPLE CREATION To support and enhance their commitment to customer satisfaction, Blue Diamond Herbs can leverage InstantGMP’s Make-To-Order Electronic Batch Record feature to efficiently generate product samples for their client’s marketing and physician/prescriber outreach initiatives.
A COMPREHENSIVE MASTER PRODUCTION RECORD PLATFORM Blue Diamond Herbs’ diverse product line, which includes gummies, kava, and Kratom, demands a powerful Master Production Record platform. InstantGMP’s solution ensures seamless coordination and control over the entire production process, from formulation to finished product.
CONFIGURABILITY FEATURES FOR EXPANSION Anticipating growth, Blue Diamond Herbs appreciates InstantGMP’s configurability features. The software can adapt seamlessly to accommodate expansion, providing the flexibility needed to meet evolving business demands.
Luke Didio, Founder and President of Blue Diamond Herbs, expressed his excitement about their investment in InstantGMP™ PRO software, stating, “We believe that excellence in manufacturing is the cornerstone of our success in the Kratom industry. InstantGMP™ PRO software aligns perfectly with our commitment to quality and efficiency. We are confident that this partnership will empower us to achieve our goals and provide the highest level of service to our customers.”
InstantGMP is proud to welcome Blue Diamond Herbs into our circle of valued clients. This collaboration marks a significant step towards ensuring GMP and FDA compliance while driving operational excellence in manufacturing.
“The reBEAT system stands out for its unique non-blood-contacting feature, the ability to support both ventricles, and its patient-specific design. Notably, it can be implanted within minutes on a beating heart by a heart team (comprising cardiologists, surgeons, and anesthesiologists) without sutures. Its avoidance of blood-contact eliminates potential complications such as strokes and bleeding, significantly enhancing patient care and quality of life,” explained Prof. Wildhirt. He added, “Our company has worked closely with esteemed medical professionals and research teams, and has achieved remarkable progress in the field of mechanical circulatory support.”
Professor Stephan Schueler, the UK Principal Investigator from Freeman Hospital, Newcastle upon Tyne, underscored the interdisciplinary potential of reBEAT and said, “The heart team and anesthesiologists involved in this trial have been very keen to learn more about how this pulsatile device physiologically enhance cardiac performance – not only to improve overall circulation, but also the potential beneficial effects on the heart itself. Notably, reBEAT’s unique characteristic of not requiring anticoagulation is set to significantly reduce the risk of bleeding complications, making it a safer alternative for patients than incumbent technologies.”
PD Dr. Bastian Schmack, the German Principal Investigator from Hannover Medical School, shared these positive views on the outcomes from the initial implantations of reBEAT and what it implies for future treatment, “simplicity and safety of the procedure holds a very high potential to significantly reduce patient recovery time. Shorter recovery periods will alleviate pressure on healthcare facilities and enhance the overall quality of care for patients, especially those requiring mechanical cardiac support.”
Professor Arjang Ruhparwar, Chief of the Department of Cardiothoracic, Transplantation, and Vascular Surgery at Hannover Medical School, emphasized the groundbreaking nature of reBEAT noted, “the device’s unique pulsatility and non-blood-contacting nature reduce the risk of thrombosis. This has potential implications for enhancing the patient’s overall immune response, crucial for the success of treatments like heart transplantation.”
The collaborative efforts with the AdjuCor team have spanned several years, leading to crucial insights into the functionality and effectiveness of the reBEAT device. Professor Ulrich Stock, Proctor of the study and affiliated with Harefield Hospital, London, expressed enthusiasm about the successful translation of developmental improvements into the clinical settings. He also highlighted the remarkable finding of the study’s expert group of anesthesiologists, comprising Dr. Henning Pauli, PD Dr. Jan Karsten and Dr. Vikrant Pathania, regarding the ability to assess the device by echocardiography. Their expertise further emphasized the device’s potential for revolutionizing cardiac care.
“AdjuCor is dedicated to advancing medical technology, and reaching this stage in our first-in-human clinical study represents a significant milestone in our commitment towards improving patient outcomes. Our team continues to collaborate with experts in the field, driving innovation and paving the way for a future where advanced cardiac care is accessible, efficient, and safe for all,” noted Prof. Wildhirt.
26 million people world-wide suffer from heart failure. Unlike traditional treatments such as heart transplantation and mechanical blood pumps, the patented technology of AdjuCor’s reBEAT represents a revolutionary advancement in treatment of advanced heart failure patients. Its unique feature lies in its ability to be swiftly implanted around the beating heart and to support the failing heart without the complications associated with blood-contact, such as strokes and bleeding. AdjuCor’s innovative technology represents an entirely new chapter in the landscape of cardiac support care and aims to transform the lives of these patients world-wide.
About AdjuCor
AdjuCor GmbH is headquartered in Munich, Germany, and founded in 2012 by renowned cardiothoracic surgeon Prof. Stephen Wildhirt. AdjuCor’s journey from research to clinical application has been supported by the European Commission including funding from the EIC, alongside German and private investors. With over €42 million in funding and a team of 30+ experts, the company is on the brink of revolutionizing heart failure treatment.
About EIC
The European Innovation Council (EIC) is Europe’s flagship innovation program that provides funding and support for high-impact projects in the fields of technology and innovation. The EIC supports projects with the potential to create jobs, improve quality of life, and drive economic growth.
Dr. Mike Acanfora will serve as Director of Chiropractic for The Spine & Sports Health Center, welcoming current and new chiropractic patients.
BAYONNE, N.J., Oct. 20, 2023 /PRNewswire-PRWeb/ — The Spine & Sports Health Center, a leading Hudson County based pain management center, is proud to announce the addition of Dr. Michael Acanfora as Director of Chiropractic. Dr. Acanfora, known by his patients as “Dr. Mike,” is a well-respected chiropractor and the founder of The Wellness Institute in Bayonne, NJ, a trusted community chiropractic practice for 30 years. In his new role, Dr. Acanfora and his team will provide care for current and new chiropractic patients at The Spine & Sports Health Center’s Bayonne, Jersey City and Hoboken locations.
As a doctor who is passionate about wellness and helping patients maximize their health potential, Dr. Acanfora sees this transition as an opportunity to support even more people in the community. “Empowering individuals to embrace a naturally healthy and joyful life has always been the driving force behind my approach to chiropractic care,” states Dr. Acanfora. “I’m excited by the prospect of sharing the principles of chiropractic care and holistic wellness to even more people in my community.”
“Chiropractic care is an important part of our pain management service offerings, and we are excited to embark on this new partnership with Dr. Acanfora,” says Dr. Alex Visco, Founder and Medical Director of The Spine & Sports Health Center. “Dr. Acanfora shares our vision of providing a holistic approach to long-lasting pain relief and wellness. Together, we are dedicated to empowering our patients with the tools they need to achieve optimal health. This collaboration marks a significant step towards enhancing the quality of care we provide and ensuring that our patients receive comprehensive solutions for their pain.”
A Bayonne native, Dr. Acanfora earned his undergraduate degree from Kean University and his Doctor of Chiropractic from Life University. Throughout his career Dr. Acanfora has devoted much of his time to community health education. In 2018, he co-founded The Health Coaching Academy in order to increase public awareness of chiropractic techniques.
The Spine & Sports Health Center has pain management locations in Jersey City, Bayonne, and Hoboken. Current and future patients of Dr. Acanfora may call 201-535-2474 to schedule an appointment.
ASHEVILLE, N.C., Oct. 19, 2023 /PRNewswire/ — The Centers for Disease Control reports, “Every second an adult in the U.S. falls.” Additional CDC research shows falls are the leading cause of injury and death in people over age 65. To help you be proactive in taking preventive measures,…
These lists were developed as the result of a national survey with more than 2,000 medical experts from doctors, surgeons, plastic surgery clinic managers, and health care professionals working in plastic surgery. During the survey period, over 8,400 votes were collected and analyzed for each cosmetic surgery procedure. Participants were asked to name the leading plastic surgeons for each cosmetic procedure in their own state as well as provide the same for out-of-state surgeons. The recommendations portion of the national survey counts as 85% of the total overall scores.
The participants were then asked to assess the quality of care (e.g., consultation with doctor, complications, follow-up care, outcome) to further differentiate the perceived reputation of each plastic surgeon. These answers, along with accreditation statuses were used to calculate the associated quality score portion, which weighs as the remaining 15% of the total overall scores.
In the end, the survey results identified 358 individual surgeons which were then ranked into lists of the top 150 in each of the five specialties, with the specific rankings based on their total overall score.
Dr. Rohrich received the highest overall score and thus was ranked at the top of the list as the number one best liposuction plastic surgeon in the country. Dr. Rohrich also appears in each of the other procedure ranked lists; number one in facelift, number one in eyelid surgery, number one in rhinoplasty, as well as number three in the breast augmentation category.
Dr. Rohrich uses an advanced technique of body contouring surgery combining ultrasound-assisted liposuction to obtain more uniform results, with a super-wet technique of liposuction to enhance overall safety. He has written extensively on this procedure and has demonstrated and taught this technique to thousands of plastic surgeons worldwide.
“Every person has their own unique physical characteristics and anatomy,” says Dr. Rohrich. “It is imperative that prospective patients have an honest discussion with their plastic surgeon regarding goals and expectations in order to ensure the most successful outcomes. Liposuction is an art and a science, as is all of plastic surgery.”
About Rod J. Rohrich, M.D., F.A.C.S.
Dr. Rod J. Rohrich is a board certified plastic surgeon in Dallas, Texas. He was named the top plastic surgeon in America by Newsweek in both rhinoplasty and facelift surgery in 2021, 2022 and 2023. Dr. Rohrich is a Clinical Professor of Plastic Surgery at Baylor College of Medicine. He was the first Chair of the Department of Plastic Surgery as well as the first plastic surgeon selected as a Distinguished Teaching Professor at UT Southwestern Medical Center. He graduated from Baylor College of Medicine with high honors and completed his plastic surgery training at the University of Michigan Medical Center and fellowships at Massachusetts General Hospital/Harvard (hand/microsurgery) and Oxford University (pediatric plastic surgery). He is Chair of the Dallas Rhinoplasty Meeting, Founding Chair of the Dallas Cosmetic Surgery and Medicine Meeting, Founding Member of the Alliance in Reconstructive Surgery, and a Founding Partner of the Dallas Plastic Surgery Institute.
He is the immediate past (after serving for 18 years) Editor-in-Chief of the most respected global peer reviewed plastic surgery journal – the Plastic and Reconstructive Surgery Journal. He is Founding Editor-in-Chief/Editor Emeritus of the first open access peer reviewed plastic surgery journal, PRS Global Open. Dr. Rohrich has published over 1000 peer reviewed articles and seven textbooks in plastic surgery including a best-selling medical book entitled The Facial Danger Zones. Dr. Rohrich recently published an innovative cosmetic surgery video atlas, Cosmetic Surgery by the Masters.
Dr. Rohrich also served as president of the American Society of Plastic Surgeons (ASPS), the largest organization of board certified plastic surgeons in the world. He repeatedly has been selected by his peers as one of America’s best doctors. He received the ASPS Special Achievement Award and on three occasions has received one of his profession’s highest honors, the Plastic Surgery Foundation (PSF) Distinguished Service Award, which recognizes his contributions to education in plastic surgery. In addition, he has also been recognized by the PSF with the Plastic Surgery Foundation Distinguished Career Researcher Award for his contributions to plastic surgery research and innovations. He is also the recipient of the ASPS 2022 Honorary Citation.
As an example, glucose stimulation of the EndoC-̒H5 cells will result in the secretion of insulin in a dynamic manner and this secretion can be enhanced by GLP-1 (glucagon‐like peptide) and GIP (glucose‐dependent insulinotropic polypeptide) analogs. In this way, EndoC-̒H5 based disease models for T1 and T2 diabetes, allow lead identification and optimization in drug development without compromising highly reproducible results and providing an accurate understanding of beta-cell function. Thus, showing that EndoC-̒H5 cells can grant relevant early drug discovery through beta-cell function characterization and target identification and validation approaches.
Join the featured speakers as they discuss existing models and solutions for biomedical research and drug development in diabetes based on the newly developed EndoC-̒H5 primary-like human beta cells, which combine robust glucose-stimulated insulin secretion and GLP-1/GIP receptor activities and modeling of human T1 & T2 diabetes.
Join Bruno Blanchi, PhD, Chief Scientific Officer, Human Cell Design; and Miguel Sáinz Jaspeado, PhD, Scientific Affairs Manager, Mercodia, for the live webinar on Thursday, November 02, 2023, at 9:30am EDT (2:30pm CET/EU-Central).
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
The use of ML to augment and complement the use of animal models in preclinical research
Techniques supporting improved preclinical toxicological knowledge and toxicogenomic research
Applying chemical pattern analysis and bioanalytics to predict drug interactions and support drug repositioning
Concepts of bias and explainability in preclinical AI model development
Join Dr. Szczepan Baran, MS, VMD, CSO, VeriSIM Life; and Dr. Weida Tong, PhD, Director, Division of Bioinformatics and Biostatistics, FDA National Center for Toxicological Research, for the live webinar on Monday, October 30, 2023, at 1pm EDT (5pm GMT/UK).
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
Join this webinar to gain insights into the SCAN2 algorithm and how it enables single-cell sequencing with high accuracy for somatic mutations.
Join Peter J. Park, PhD, Professor of Biomedical Informatics, Harvard Medical School; and Lovelace J. Luquette, PhD, Postdoctoral Fellow, Harvard Medical School, for the live webinar on Tuesday, October 31, 2023, at 1pm EDT (10am PDT).
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
